Compare Cassava Sciences Inc (FLNA) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Marsh & McLennan Companies, Inc. trades at $181.06 (market cap $84.90B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 1597.7× Cassava Sciences Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.25% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MRSH | |
|---|---|---|
Market Cap | $53.14M | $84.90B |
Sector | Health | Financials |
52-Week High | $4.64 | $212.28 |
52-Week Low | $1.09 | $157.32 |
Enterprise Value | -$33.43M | $105.74B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Marsh (MRSH) trades at $178.05, down 1.92% on the day, near the analyst consensus low target of $175. The stock shows bullish technical signals with strong moving average support, while recent quarterly earnings have consistently beaten expectations. The company maintains solid profitability with a 14.26% net margin and 27.42% ROE, supported by a 10% dividend increase announced in July 2026. Revenue growth has been steady, reaching $26.98B in 2025, though profit margins show slight compression from previous years.
The outlook remains balanced with strong fundamentals and shareholder returns offset by valuation concerns and rising cost pressures. Investment opportunity centers on consistent earnings beats, dividend growth, and AI initiatives through Oliver Wyman. Key risks include premium valuation multiples, softer insurance pricing tailwinds, and execution challenges in sustaining organic growth as operating expenses rise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
